Risperidone: Switching from brand name to generic

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 5, 2010, Pages 457-458

  Hardan, Antonio Y ^a   Fung, Lawrence K ^a   Amin, Hitha ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; RISPERIDONE;

AGGRESSION; AUTISM; AUTOMUTILATION; BIPOLAR DISORDER; DRUG SUBSTITUTION; HUMAN; HYPERACTIVITY; INTELLECTUAL IMPAIRMENT; IRRITABILITY; LETTER; SCHIZOPHRENIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; DRUGS, GENERIC; FEMALE; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA, PARANOID; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 77958523394     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2010.0013     Document Type: Letter

References (4)

1. Borgheini G: The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 25:1578-1592, 2003.
2. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K: Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 62(Suppl 5):14-17; discussion 23-14, 2001.
3. MICROMEDEX: Tradename List for risperidone. Thomson Rueters Healthcare; 2009.
4. Shuren J: Requirements for submission of bioequivalence data; Final rule. Fed Regist 74:2849-2862, 2009.